



**IN THE NATURE OF ABRIDGED PROSPECTUS - MEMORANDUM CONTAINING SALIENT FEATURES OF THE RED HERRING PROSPECTUS  
DATED NOVEMBER 25, 2024 (THE "RHP"). YOU ARE ENCOURAGED TO READ GREATER DETAILS AVAILABLE IN THE RHP.**

**BIDDER'S UNDERTAKING AND CONFIRMATION FOR BID CUM APPLICATION FORM**

(IN CASE OF A JOINT BID, THE CONFIRMATIONS, AUTHORISATIONS, UNDERTAKINGS AND REPRESENTATIONS MADE BY THE FIRST BIDDER WILL BE DEEMED TO HAVE BEEN MADE ON BEHALF OF ALL THE JOINT BIDDERS. THE FIRST BIDDER SHALL BE LIABLE FOR ALL THE OBLIGATIONS ARISING OUT OF THE OFFER OF EQUITY SHARES.)

The Equity Shares offered in the Offer have not been and will not be registered, listed or otherwise qualified in any jurisdiction except India and may not be offered or sold, and Bids may not be made by persons in any such jurisdiction, except in compliance with the applicable laws of such jurisdiction.

On the basis of the RHP, which was filed with the Registrar of Companies, West Bengal at Kolkata (the "RoC") (if I am/we are in India) or the preliminary international wrap dated November 25, 2024 (the "Preliminary International Wrap" and together with the RHP, the "Preliminary Offering Memorandum") (if I am/we are outside India), the general information document for Investing in Public Offers ("GID") and having studied the attached details as per the Abridged Prospectus, I/we hereby apply for Allotment to me/us of the Equity Shares in the Offer up to my/ our Bids for the maximum number of Equity Shares at or above the Offer Price, to be discovered through the Book Building Process. I/we hereby confirm that I am/we are eligible persons/s to invest in the Offer in accordance with applicable laws. The amount payable on Bidding has been blocked in the ASBA Account with the relevant SCSB or the bank account linked with the UPI ID (in case of UPI Bidders using UPI Mechanism) as mentioned in this Bid cum Application Form, as the case may be. I/we hereby confirm that I/we do not require approval from any regulatory authority to invest in the Offer according to applicable laws. I/we agree to accept the Equity Shares Bid for, or such lesser number as may be Allotted to me/us subject to the terms of the RHP (if I am/we are in India), the Preliminary Offering Memorandum (if I am/we are outside India), Abridged Prospectus, the GID, the Bid cum Application Form and other applicable laws. I/we undertake that I/we will sign all such other documents and do all such acts, if any, necessary on my/our part to enable me/us to be registered as the holder(s) of the Equity Shares which may be Allotted and to register my/our address (as given in the Depository records and to place my/our name on the register of members of the Company. I/we acknowledge that in case of QIB Bidders, only the SCSBs (for Bids other than the Bids by Anchor Investors), and the Book Running Lead Managers ("BRLMs") and the Syndicate Member(s) (only in the Specified Locations) have the right to reject Bids (including on technical grounds) at the time of acceptance of Bid cum Application Form provided that the reasons for rejecting the same shall be provided to such Bidder in writing, whereas it has a right to reject it from Non-Institutional Bidders and Retail Individual Bidders based only on technical grounds and/or as specified in the Abridged Prospectus, GID and the RHP or the Preliminary Offering Memorandum, as applicable. I/we authorise the Company to make the necessary changes in this Bid cum Application Form and the RHP for filing of the Prospectus with the RoC without intimation to me/us and use this Bid cum Application Form as the application form for the purpose of the Offer.

I/we represent, warrant, acknowledge and agree with the Company, the Selling Shareholders and the BRLMs as follows: (A) I/we have received a copy of the RHP (if I am/we are in India) or the Preliminary Offering Memorandum (if I am/we are outside India) and that my/our investment decision is based on the RHP or the Preliminary Offering Memorandum, as applicable; (B) I/we understand that the Equity Shares offered in the Offer have not been and will not be registered, listed or otherwise qualified in any jurisdiction except India and that such Equity Shares may not be offered or sold, and Bids may not be made by persons in any jurisdiction outside India, except in compliance with the applicable laws of such jurisdiction; (C) if I am/we are outside India, I/we have read the section "Selling Restrictions" of the Preliminary International Wrap and I am/we are able to purchase the Equity Shares in accordance with the laws that are applicable to me/us; (D) I/we understand that the Equity Shares offered in the Offer have not been and will not be registered under the U.S. Securities Act of 1933, as amended ("U.S. Securities Act"), or the securities laws of any state of the United States and are being offered and sold to me/us in reliance on Regulation S under the U.S. Securities Act ("Regulation S"); (E) I/we represent that I was/were outside the United States (within the meaning of Regulation S) at the time the offer of the Equity Shares offered in the Offer was made to me/us and I am/we are currently outside the United States (within the meaning of Regulation S); (F) I/we hereby make the representations, warranties, acknowledgments and agreements contained in (i) the sections "Other Regulatory and Statutory Disclosures" and "Offer Procedure" of the RHP and (ii) if I am/we are outside India, the sections "Selling Restrictions" and "Transfer Restrictions" of the Preliminary International Wrap; (F) I/we agree to abide by this Bid cum Application Form and the RHP (I am/we are in India) or the Preliminary Offering Memorandum (I am/we are outside India), together with the terms and conditions contained therein; (G) I am/we are not an affiliate of the Company or applying to purchase Equity Shares on behalf of an affiliate of the Company; (H) I/we agree to indemnify and hold the Company and the members of the Syndicate harmless from any and all costs, claims, liabilities and expenses (including legal fees and expenses) arising out of or in connection with any breach of these representations, warranties or agreements and I/we agree that the indemnity set forth in herein shall survive the resale of the Equity Shares purchased in the Offer; (I) if I am/we are making an application to acquire any of the Equity Shares as fiduciary or agent for one or more investor accounts, I/we have sole investment discretion with respect to each such account and I/we have full power to make the foregoing representations, warranties, acknowledgments and agreements on behalf of each such account; and (J) if I am/we are making an application to acquire any of the Equity Shares for one or more managed accounts, I am/we are authorized in writing by each such managed account to subscribe to the Equity Shares for each such managed account and to make (and I/we hereby make) the representations, warranties, acknowledgments and agreements herein for and on behalf of each such account, reading the reference to "I/we" to include such accounts.

**FOR QIB BIDDERS:** We confirm that the Bid size/maximum Equity Shares applied for by us does not exceed the relevant regulatory approvals/limits. We are not prohibited from accessing capital markets under any order/ruling/judgment of any regulatory, judicial or any other authority, including Securities and Exchange Board of India ("SEBI") or under the provisions of any law, regulation or statute.

**Further:** 1) In accordance with ASBA process provided in the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended ("SEBI ICDR Regulations") and as disclosed in the RHP or the Preliminary Offering Memorandum, as applicable, I/we undertake (a) the Members of the Syndicate (in Specified Locations only) or the Registered Brokers (at Broker Centres) or the SCSBs (at Designated SCSB Branches) or the RTAs (at Designated RTA Locations), as the case may be, to do all acts as are necessary to make the application in the Offer, including uploading my/our Bid, blocking, unblocking of funds in my/our bank account maintained with the SCSB as specified in the Bid cum Application Form or in my/our bank account linked with the UPI ID provided in the Bid cum Application Form, as the case may be, transfer of funds to the Public Offer Account on receipt of instruction from Registrar to the Offer or the Sponsor Banks, as the case may be, after finalisation of Basis of Allotment; and (b) the Registrar to the Offer or Sponsor Banks, as the case may be, to issue instruction to the SCSBs to unblock the funds in the specified bank account upon finalisation of the Basis of Allotment. 2) In case the amount available in the specified bank account is insufficient as per the highest Bid Offer, the SCSB/Registrar to the Offer shall reject the application. 3) I/we hereby authorise the Members of the Syndicate (in Specified Locations only) or the Registered Brokers (at Broker Centres) or the SCSBs (at Designated SCSB Branches) or CDPs (at Designated CDP locations) or the RTAs (at Designated RTA locations), as the case may be, to make relevant revisions as may be required to be done in the Bid, in the event of a revision of the Price Band.

I/we hereby provide my/our consent to the Stock Exchanges / Sponsor Banks / NPCI / Registrar to the Offer for collecting, storing and usage validating my/our PAN details from the bank account where my / our amount is blocked by the relevant SCSBs.

I/we acknowledge that as per existing policy of the Government of India, OCBs cannot participate in the Offer. I am/we are not an OCB. For further details, see "Offer Procedure" and "Restrictions on Foreign Ownership of Indian Securities" beginning on pages 418 and 437, respectively, of the RHP.

**INSTRUCTIONS FOR FILLING UP THE BID CUM APPLICATION FORM**

- Name of sole/ first Bidder should be exactly the same as it appears in the Depository records. In case of joint Bids, only the name of the first Bidder (which should also be the first name in which the beneficiary account is held) should be provided in the Bid cum Application Form. The Bid means an "indication to make an offer" during the Bid/Offer Period by a Bidder and not "an offer".
- The first Bidder, should mention his/her PAN allotted under the Income Tax Act, 1961, DP ID, Client ID and UPI ID (as applicable). Except for Bids by or on behalf of the Central or State Government and the officials appointed by the courts and by investors who are exempt from the requirement of obtaining/ specifying their PAN for transacting in the securities market and by persons residing in the state of Sikkim, any other category of Bidders, including without limitation, multilateral/bilateral institutions, the Bidders, or in the case of joint Bids, the first Bidder (the first name under which the beneficiary account is held), should mention his/her PAN allotted under the Income Tax Act, 1961. Any Bid cum Application Form without the PAN is liable to be rejected other than as specified above. Investors must ensure that their PAN is linked with Aadhaar card and are in compliance with Central Board of Direct Taxes ("CBDT") notification dated February 13, 2020 and press release dated June 25, 2021, read with press release dated September 17, 2021 and CBDT circular no.7 of 2022, dated March 30, 2022, read with press releases dated March 28, 2023 and any subsequent press release in this regard.
- Based on the PAN, DP ID and Client ID provided by the Bidders, the Registrar to the Offer will obtain Demographic Details registered with Depository Participants to be used, among other things, for Allotment, technical rejections or unblocking ASBA Account. Hence, Bidders are advised to immediately update any change in their Demographic Details as appearing on the records of the Depository Participant to ensure accuracy of records. Please note that failure to do so could result in failure in Allotment and delay in unblocking of ASBA Account at the Bidders' sole risk and neither the Members of the Syndicate nor the Registered Brokers nor the Registrar to the Offer nor RTAs/CDPs nor the SCSBs nor the Company nor the Selling Shareholders shall have any responsibility and undertake any liability for the same.
- Bid Lot and Price Band:** The face value of Equity Shares is ₹ 2/- each. The Price Band and the minimum Bid Lot size has been decided by the Company in consultation with the BRLMs. The Price Band and Minimum Bid Lot size for the Offer has been or will be advertised in all editions of the English national daily newspaper Financial Express, all editions of the Hindi national daily newspaper Jansatta and Kolkata edition of Damik Statesman, a Bengali daily newspaper (Bengali being the regional language of West Bengal, where our Registered and Corporate Office is located), at least two (2) Working Days before the Bid/Offer Opening Date, with the relevant financial ratios calculated at the Floor Price and the Cap Price and will be made available to the BSE Limited ("BSE") and National Stock Exchange of India Limited ("NSE"), and together with BSE, the "Stock Exchanges" for the purpose of uploading on their respective websites in accordance with SEBI ICDR Regulations. In case of revision of the Price Band, the Bid/Offer Period will be extended for at least three (3) additional Working Days after revision of Price Band subject to the Bid/ Offer Period not exceeding a total of ten (10) Working Days. In cases of force majeure, bank strike or similar unforeseen circumstances, the Company in may, for reasons to be recorded in writing, extend the Bid/Offer Period for a minimum of one (1) Working Days, subject to the Bid/Offer Period not exceeding ten (10) Working Days. Any revision in the Price Band and the revised Bid/Offer Period, if applicable, will be widely disseminated by notification to the Stock Exchanges, by issuing a public notice and also by indicating the changes on the websites of the BRLMs, and at the terminals of the Members of the Syndicate and by intimation to Self Certified Syndicate Banks ("SCSBs"), other Designated Intermediaries and the Sponsor Banks as applicable.
- Maximum and Minimum Bid Size:** In case of Retail Individual Bidders, such number of Equity Shares in multiples of the minimum Bid Lot such that the Bid Amount does not exceed ₹ 200,000. Bids at the Cut-Off Price indicate their agreement to purchase the Equity Shares at the Offer Price, as determined at the completion of the Book Building Process. In case of Non-Institutional Bidders and QIB Bidders, the minimum Bid size shall be such number of Equity Shares in multiples of the minimum Bid Lot such that Bid Amount exceeds ₹ 200,000. The maximum Bid by any investor should not exceed the investment limits prescribed for them by applicable laws and/or the Offer size mentioned in the RHP or Preliminary Offering Memorandum, as applicable.
- Please tick category as applicable to ensure proper upload of Bid in Stock Exchanges system.
- Please tick investor status as applicable. Please ensure investor status is updated in your Depository records.
- Cheques/Demand Draft/Cash/stock invest/money orders/postal orders will not be accepted.** Eligible NRIs bidding on a non-repatriation basis by using the Resident Bid cum Application Form are required to authorise their SCSB to confirm or accept the UPI Mandate Request (in case of UPI Bidders bidding through the UPI Mechanism), block their Non-Resident Ordinary (NRO) Accounts for the full Bid Amount, at the time of the submission of the Bid cum Application Form. All Bidders including the Eligible NRIs bidding on a repatriation basis by using the Non-Resident Forms should authorize their respective SCSB to confirm or accept the UPI Mandate Request (in case of UPI Bidders) to block their Non-Resident External ("NRE") accounts (including UPI ID, if activated), or Foreign Currency Non Resident ("FCNR") Accounts. All Bidders including the Eligible NRIs Bidding on a non-repatriation basis can obtain the Bid cum Application Form from the Registered Office of the Company or from any of the Members of the Syndicate or CDPs or RTAs or Registered Brokers from the Bidding Centers. In accordance with applicable law and UPI Circulars, Bidders to please ensure that SCSB where the ASBA Account is maintained has notified at least one branch in the location where Bid cum Application Forms will be deposited by Designated Intermediaries.
- Please note that application made using third party UPI ID or third party ASBA Bank Account are liable to be rejected.
  - QIBs and Non-Institutional Bidders with Bids with a Bid Amount more than ₹ 500,000 cannot use UPI Mechanism to apply. UPI Bidders applying up to ₹ 500,000 shall apply through UPI mode as per NPCI vide circular reference no. NPCI/UPI/OC No. 127/2021-22 dated December 09, 2021 read with SEBI circular no. SEBI/HO/CFD/DIL2/CIR/P/2022/45 dated April 5, 2022.
  - For Retail Individual Bidders (RIBs) and Non-Institutional Bidders with Application size up to Rs. 500,000 ("UPI Bidders") bidding through the UPI Mechanism:**
    - Please ensure that your bank is offering UPI facility for public offers.
    - Please mention UPI ID clearly in CAPITAL LETTERS only.
    - Ensure that the: (a) bank where the bank account linked to their UPI ID is maintained; and (b) Bidders Bidding using the UPI Mechanism may apply through the SCSBs and mobile applications whose names appears on the website of the SEBI (<https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedfpi=yes&intmid=40>) and (<https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedfpi=yes&intmid=43>) respectively, as updated from time to time.
    - Eligible NRIs applying in the Offer through the UPI Mechanism, are advised to ensure with the relevant bank where their account is UPI linked prior to submitting their Bid cum Application Form.
    - UPI ID cannot exceed 45 characters.
    - Please ensure that you are using your UPI ID only and not the UPI ID of any third party.
    - UPI Bidders Bidding using the UPI Mechanism shall ensure that details of the Bid are reviewed and verified by opening the attachment in the UPI Mandate Request and then proceed to authorise the UPI Mandate Request using his/her UPI PIN. For further details, see "Offer Procedure" on page 418 of the RHP.
- Only the Sole Bidder/first Bidder to sign the Bid cum Application Form /Revision Form. Thumb impressions and signatures other than in the languages specified in the Eighth Schedule to the Constitution of India must be attested by a Magistrate or a Notary Public or a Special Executive Magistrate under official seal. Signature of ASBA Account holder is mandatory. If the first Bidder is not the account holder, ensure that the Bid cum Application Form is signed by the account holder. Necessary revisions in the Bidders' undertaking and instructions will be required depending upon the jurisdiction in which the sale of shares is proposed.
- Other Instructions:** a. Bids must be made only in the prescribed Bid cum Application Form; b. Bids must be completed in full, in BLOCK LETTERS in ENGLISH. Bidders should note that the Members of the Syndicate, Registered Broker, CDPs, RTAs, and/or SCSBs will not be liable for errors in data entry due to incomplete or illegible Bid cum Application Forms; and c. Ensure that all applicable documents in support of the Bid are attached with the Bid cum Application Form.
- The Bidders may note that in case the DP ID, Client ID and PAN mentioned in the Bid cum Application Form and entered into the electronic bidding systems of the Stock Exchanges do not match with the DP ID, Client ID and PAN available in the Depository database, the Bid cum Application Form is liable to be rejected. Investors must ensure that their PAN is linked with Aadhaar card and are in compliance with CBDT notification dated February 13, 2020 and press release dated June 25, 2021, read with press release dated September 17, 2021 and CBDT circular no. 7 of 2022, dated March 30, 2022, read with press release dated March 28, 2023 and any subsequent press releases in this regard. You may send the RHP and the Prospectus (if you are Resident in India) or the Preliminary Offering Memorandum and the final offering memorandum (if you are Resident outside India) either in physical form or electronic form or both. You shall not distribute or forward these documents and these documents are subject to the disclaimers and restrictions contained in or accompanying them.

**Note:** Terms used but not defined herein shall have the meaning assigned to such terms in the RHP. For detailed instructions for filling the various fields of this Bid cum Application Form, please refer to the GID, which is also available on the respective websites of the BRLMs and the Stock Exchanges.

**TEAR HERE**

	COMPANY CONTACT DETAILS	REGISTRAR TO THE OFFER CONTACT DETAILS
<ul style="list-style-type: none"><li>In case of queries related to Allotment/ credit of Allotted Equity Shares, the Bidders should contact Registrar to the Offer.</li><li>In case of Bids submitted to the SCSBs, the Bidders should contact the relevant SCSB.</li><li>In case of queries related to upload of Bids submitted to the relevant Members of the Syndicate / RTAs / Registered Brokers / CDPs, as applicable, the Bidders should contact the relevant Designated Intermediary.</li><li>For UPI related queries, investors can contact NPCI at the toll free number:- 18001201740 and Mail ID: ipo.upi@npci.org.in and the Registrar to the Offer at Tel.: +91 40 6716 2222 and E-mail: sdi.ipo@kfintech.com</li><li>In case of ASBA Bidders (other than 3-in-1 Bids) for a Bid above ₹ 500,000, ensure that the Bid is uploaded only by the SCSBs.</li><li>Ensure that you have accepted the UPI Mandate Request received from the Sponsor Banks prior to 5:00 p.m. of the Bid/ Offer Closing Date.</li></ul>	<p><b>SURAKSHA DIAGNOSTIC LIMITED</b> <b>Registered and Corporate Office:</b> Plot No. DG-12/1, Action Area 1D, Premises No. 02-0327, New Town, Rajarhat, Kolkata 700 156 West Bengal, India; Tel: +91 33 66059750 <b>Contact Person:</b> Mamta Jain, Company Secretary and Compliance Officer; E-mail: investors@surakshanet.com <b>Website:</b> www.surakshanet.com <b>Corporate Identity Number:</b> U85110WB2005PLC102265</p>	<p><b>KFIN TECHNOLOGIES LIMITED</b> Selenium Tower B, Plot No. 31 and 32, Financial District, Nanakramguda, Serilingampally Hyderabad -500 032, Telangana, India; <b>Telephone Number:</b> +91 40 6716 2222 <b>Toll Free No.:</b> 18003094001 <b>Email:</b> sdi.ipo@kfintech.com; <b>Website:</b> www.kfintech.com <b>Investor Grievance E-mail:</b> einward.ris@kfintech.com <b>Contact Person:</b> M. Murali Krishna; <b>SEBI Registration Number:</b> INR0000000221</p>

# IN THE NATURE OF ABRIDGED PROSPECTUS - MEMORANDUM CONTAINING SALIENT FEATURES OF THE RED HERRING PROSPECTUS



(Please scan this QR code to view this Abridged Prospectus)

This is an abridged prospectus containing salient features of the red herring prospectus of Suraksha Diagnostic Limited (the "Company") dated November 25, 2024, filed with the Registrar of Companies, West Bengal at Kolkata (the "RHP" or "Red Herring Prospectus"). You are encouraged to read greater details available in the RHP, which is available at <https://www.sebi.gov.in/sebiweb/home/HomeAction.do?doListing=yes&sid=3&ssid=15&smid=11>. Unless otherwise specified all capitalised terms used herein and not specifically defined bear the same meaning as ascribed to them in the RHP.

**THIS ABRIDGED PROSPECTUS CONSISTS OF FOUR PAGES OF BID CUM APPLICATION FORM ALONG WITH INSTRUCTIONS AND EIGHT PAGES OF ABRIDGED PROSPECTUS. PLEASE ENSURE THAT YOU HAVE RECEIVED ALL THE PAGES.**

Please ensure that you have read the RHP, this abridged prospectus ("Abridged Prospectus") and the general information document for investing in public issues ("GID") undertaken through the Book Building Process before applying in the Offer (as defined below). The investors are advised to retain a copy of the RHP/Abridged Prospectus for their future reference.

You may obtain a physical copy of the Bid-cum-Application Form and the RHP from the Stock Exchanges (defined below), Members of the Syndicate (defined below), Registrar to the Offer, Registrar and Share Transfer Agents ("RTAs"), Collecting Depository Participants ("CDPs"), Registered Brokers, Bankers to the Offer, Investors' Associations or Self Certified Syndicate Banks ("SCSBs"). You may also download the RHP from the website of Securities and Exchange Board of India ("SEBI") at [www.sebi.gov.in](http://www.sebi.gov.in), the website of National Stock Exchanges of India Limited ("NSE") and the BSE Limited ("BSE") and together with NSE, the "Stock Exchanges" at [www.nseindia.com](http://www.nseindia.com) and [www.bseindia.com](http://www.bseindia.com) the website of the Company at [www.surakshanet.com](http://www.surakshanet.com) and the website of the Book Running Lead Managers at [www.icicisecurities.com](http://www.icicisecurities.com), [www.nuvama.com](http://www.nuvama.com) and [www.sbicaps.com](http://www.sbicaps.com)

## Suraksha

Clinic & Diagnostics

### SURAKSHA DIAGNOSTIC LIMITED

Corporate Identity Number: U85110WB2005PLC102265; Date of Incorporation: March 15, 2005

Registered office and Corporate office	Contact Person	Email and Telephone	Website
Plot No. DG-12/1, Action Area 1D, Premises No. 02-0327, New Town, Rajarhat, Kolkata 700 156 West Bengal, India.	Mamta Jain <i>Company Secretary and Compliance Officer</i>	Email: <a href="mailto:investors@surakshanet.com">investors@surakshanet.com</a> Telephone: +91 33 66059750	<a href="http://www.surakshanet.com">www.surakshanet.com</a>

### OUR PROMOTERS: DR. SOMNATH CHATTERJEE, RITU MITTAL AND SATISH KUMAR VERMA

Type of Offer	Fresh Issue Size	Offer for Sale size	Total Offer Size	DETAILS OF OFFER TO PUBLIC Offer under Regulation 6(1) of the SEBI ICDR Regulations	Share Reservation among QIBs, NIBs & RIBs		
					QIBs	NIBs	RIBs
Offer for Sale	Not Applicable	Up to 19,189,330 Equity Shares of face value ₹2 each aggregating up to ₹[●] million	Up to 19,189,330 Equity Shares of face value ₹2 each aggregating up to ₹[●] million	The Offer is being made through the Book Building Process, in terms of Rule 19(2)(b) of the Securities Contracts (Regulation) Rules, 1957, as amended ("SCRR") read with Regulation 31 of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended ("SEBI ICDR Regulations") and in compliance with Regulation 6(1) of the SEBI ICDR Regulations. For further details, see 'Other Regulatory and Statutory Disclosures - Eligibility for the Offer' on page 394 of the RHP. For details in relation to share reservation amongst QIBs, NIBs and RIBs see 'Offer Structure' on page 415 of the RHP.	Not more than [●] Equity Shares of face value ₹2 each	Not less than [●] Equity Shares of face value ₹2 each available for allocation	Not less than [●] Equity Shares of face value ₹2 each available for allocation

The Equity Shares are proposed to be listed on NSE and BSE. For the purposes of the Offer, BSE is the designated stock exchange (the "Designated Stock Exchange").

DETAILS OF OFFER FOR SALE BY THE SELLING SHAREHOLDERS AND WEIGHTED AVERAGE COST OF ACQUISITION			
Name of the selling shareholders	Type	Number of shares offered/amount	Weighted Average Cost Of Acquisition per Equity Share (in ₹ per equity share)*
Dr. Somnath Chatterjee	Promoter Selling Shareholder	Up to 2,132,148 Equity Shares of face value of ₹2 each aggregating up to ₹[●] million	45.50
Ritu Mittal	Promoter Selling Shareholder	Up to 2,132,148 Equity Shares of face value of ₹2 each aggregating up to ₹[●] million	49.76
Satish Kumar Verma^^	Promoter Selling Shareholder	Up to 2,132,148 Equity Shares of face value of ₹2 each aggregating up to ₹[●] million	1.60
OrbiMed Asia II Mauritius Limited^	Investor Selling Shareholder	Up to 10,660,737 Equity Shares of face value of ₹2 each aggregating up to ₹[●] million	94.38
Munna Lal Kejriwal	Individual Selling Shareholder	Up to 799,556 Equity Shares of face value of ₹2 each aggregating up to ₹[●] million	1.60
Santosh Kumar Kejriwal	Individual Selling Shareholder	Up to 1,332,593 Equity Shares of face value of ₹2 each aggregating up to ₹[●] million	1.60

Notes: ^ Surviving entity pursuant to amalgamation of OrbiMed Asia II Mauritius FDI Investments Limited (the erstwhile shareholder) into OrbiMed Asia II Mauritius Limited on November 11, 2022.

^^ Shares are jointly held by Satish Kumar Verma with Suman Verma.

\* As certified by Manian & Rao, Chartered Accountants, by way of their certificate dated November 25, 2024.



# IN THE NATURE OF ABRIDGED PROSPECTUS - MEMORANDUM CONTAINING SALIENT FEATURES OF THE RED HERRING PROSPECTUS

## PRICE BAND, MINIMUM BID LOT & INDICATIVE TIMELINES

<b>Price Band</b> <i>For details of the Price Band and the basis for the Offer Price, please refer to the price band advertisement and the section titled "Basis for the Offer Price" on page 125 of the RHP.</i>	₹ 420 per Equity Share to ₹ 441 per Equity Share of face value of ₹ 2 each.
<b>Minimum Bid Lot Size</b>	A Minimum of [•] Equity Shares and in multiples of [•] Equity Shares thereafter
<b>Bid/Offer Opens On*</b>	Friday, November 29, 2024
<b>Bid/ Offer Closes On</b>	Tuesday, December 3, 2024 <sup>(1)</sup>
<b>Finalisation of Basis of Allotment with the Designated Stock Exchange</b>	On or about Wednesday, December 4, 2024
<b>Initiation of refunds (if any, for Anchor Investors) / unblocking of funds from ASBA Account*</b>	On or about Thursday, December 5, 2024
<b>Credit of the Equity Shares to depository accounts of Allottees</b>	On or about Thursday, December 5, 2024
<b>Commencement of trading of the Equity Shares on the Stock Exchanges</b>	On or about Friday, December 6, 2024

\* Our Company in consultation with the BRLMs, may consider participation by Anchor Investors. The Anchor Investor Bid/ Offer Period shall be one Working Day prior to the Bid/ Offer Opening Date in accordance with the SEBI ICDR Regulations i.e. Thursday, November 28, 2024.

<sup>(1)</sup> UPI mandate end time and date shall be at 5:00 p.m. on the Bid/Offer Closing Date, i.e., on December 3, 2024.

<sup>^</sup> In case of (i) any delay in unblocking of amounts in the ASBA Accounts (including amounts blocked through the UPI Mechanism) exceeding two Working Days from the Bid/ Offer Closing Date for cancelled / withdrawn / deleted ASBA Forms, the Bidder shall be compensated at a uniform rate of ₹ 100 per day or 15% per annum of the Bid Amount, whichever is higher from the date on which the request for cancellation/ withdrawal/ deletion is placed in the Stock Exchanges bidding platform until the date on which the amounts are unblocked (ii) any blocking of multiple amounts for the same ASBA Form (for amounts blocked through the UPI Mechanism), the Bidder shall be compensated at a uniform rate ₹ 100 per day or 15% per annum of the total cumulative blocked amount except the original application amount, whichever is higher from the date on which such multiple amounts were blocked till the date of actual unblock; (iii) any blocking of amounts more than the Bid Amount, the Bidder shall be compensated at a uniform rate of ₹ 100 per day or 15% per annum of the difference in amount, whichever is higher from the date on which such excess amounts were blocked till the date of actual unblock; (iv) any delay in unblocking of non-allotted/ partially allotted Bids, exceeding two Working Days from the Bid/ Offer Closing Date, the Bidder shall be compensated at a uniform rate of ₹ 100 per day or 15% per annum of the Bid Amount, whichever is higher for the entire duration of delay exceeding two Working Days from the Bid/ Offer Closing Date by the SCSB responsible for causing such delay in unblocking. The BRLMs shall, in their sole discretion, identify and fix the liability on such intermediary or entity responsible for such delay in unblocking. The post Offer BRLMs shall be liable for compensating the Bidder at a uniform rate of ₹100 per day or 15% per annum of the Bid Amount, whichever is higher from the date of receipt of the investor grievance until the date on which the blocked amounts are unblocked. For the avoidance of doubt, the provisions of the e circular no. SEBI/HO/CFD/DIL2/CIR/P/2021/2480/1/M dated March 16, 2021, read with SEBI circular no. SEBI/HO/CFD/DIL2/P/CIR/2021/570 dated June 2, 2021 and SEBI circular no. SEBI/HO/CFD/DIL2/CIR/P/2022/51 dated April 20, 2022 and SEBI Circular No: SEBI/HO/MIRSD/MIRSD\_RTAMB/P/CIR/2022/76 dated May 30, 2022, and SEBI master circular no. SEBI/HO/CFD/PoD-2/P/CIR/ 2023/00094 dated June 21, 2023 in case of delays in resolving investor grievances in relation to blocking/unblocking of funds, shall be deemed to be incorporated in the agreements to be entered into by and between our Company and the relevant intermediaries, to the extent applicable.

**Details of weighted average cost of acquisition of all Equity Shares transacted over the trailing three years, 18 months and one year preceding the date of the Red Herring Prospectus:**

Period	Weighted average cost of acquisition (WACA) (in ₹)*	Lower End of the Price Band is 'X' times the WACA <sup>^</sup>	Upper End of the Price Band is 'X' times the WACA <sup>^</sup>	Range of acquisition price Lowest Price - Highest Price (in ₹)* <sup>^^</sup>
Last three years	49.29	●	●	0.00-100.21**
Last 18 months	49.29	●	●	0.00-100.21**
Last one year	49.29	●	●	0.00-100.21**

Note: Weighted average cost of acquisition (WACA) is the total cost incurred for acquiring the securities of the Company during the relevant period divided by the total number of securities acquired during the relevant period less the acquisition cost of shares transferred (if any) divided by the total number of securities sold/ transferred during the relevant period, if any

\* As certified by Manian and Rao, Chartered Accountants, pursuant to their certificate dated November 25, 2024.

\*\* The amount paid on the acquisition of CCPS has been considered as the basis for arriving at the cost of acquisition of Equity Shares on conversion of CCPS.

<sup>^</sup> To be updated in Prospectus..

**Disclaimer:** The Equity Shares offered in the Offer have not been and will not be registered, listed or otherwise qualified in any jurisdiction except India and may not be offered or sold to persons outside of India except in compliance with the applicable laws of each such jurisdiction. In particular, the Equity Shares offered in the Offer have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), or the securities laws of any state of the United States and may not be offered or sold in the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and applicable state securities laws. The Equity Shares offered in the Offer are being offered and sold only outside the United States in "offshore transactions" as defined in and in reliance on Regulation S under the U.S. Securities Act.

## RISKS IN RELATION TO THE FIRST OFFER

This being the first public issue of our Company, there has been no formal market for the Equity Shares. The face value of the Equity Shares is ₹ 2 each. The Offer Price, Floor Price or Price Band as determined by our Company in consultation with the BRLMs and on the basis of the assessment of market demand for the Equity Shares by way of the Book Building Process, as stated under "Basis for Offer Price" on page 125 of the RHP, should not be considered to be indicative of the market price of the Equity Shares after the Equity Shares are listed. No assurance can be given regarding an active and/or sustained trading in the Equity Shares nor regarding the price at which the Equity Shares will be traded after listing.

## GENERAL RISK

Investments in equity and equity-related securities involve a degree of risk and investors should not invest any funds in this Offer unless they can afford to take the risk of losing their entire investment. Investors are advised to read the risk factors carefully before taking an investment decision in this Offer. For taking an investment decision, investors must rely on their own examination of the Issuer and this Offer, including the risks involved. The Equity Shares have not been recommended or approved by the Securities and Exchange Board of India ("SEBI"), nor does SEBI guarantee the accuracy or adequacy of the contents of the Red Herring Prospectus. Specific attention of the investors is invited to "Risk Factors" on page 36 of the RHP and page 9 of this Abridged Prospectus.

## PROCEDURE

You may obtain a physical copy of the Bid cum Application Form and the RHP from the Stock Exchanges, Members of the Syndicate, Registrar to the Offer, Registrar and Share Transfer Agents ("RTAs"), Collecting Depository Participants ("CDPs"), Registered Brokers, Banker to the Offer, Investors' Associations or Self Certified Syndicate Banks ("SCSBs").

If you wish to know about processes and procedures applicable to the Offer, you may request for a copy of the RHP and/or the GID from the BRLMs or download it from the website of SEBI at [www.sebi.gov.in](http://www.sebi.gov.in), the websites of NSE and BSE at [www.nseindia.com](http://www.nseindia.com) and [www.bseindia.com](http://www.bseindia.com), respectively, and the websites of the BRLMs at [www.icicisecurities.com](http://www.icicisecurities.com), [www.nuvama.com](http://www.nuvama.com) and [www.sbicaps.com](http://www.sbicaps.com).

**IN THE NATURE OF ABRIDGED PROSPECTUS - MEMORANDUM CONTAINING SALIENT FEATURES OF THE RED HERRING PROSPECTUS**

PRICE INFORMATION OF BRLMs					
Sr. No.	Issue Name	Merchant Banker(s)	+/- % change in closing price, +/- % change in closing benchmark		
			30 <sup>th</sup> calendar days from listing	90 <sup>th</sup> calendar days from listing	180 <sup>th</sup> calendar days from listing
1	Niva Bupa Health Insurance Company Limited	I-Sec	NA*	NA*	NA*
2	Swiggy Limited	I-Sec	NA*	NA*	NA*
3	Acme Solar Holdings Limited	I-Sec, Nuvama	NA*	NA*	NA*
4	Sagility India Limited	I-Sec	NA*	NA*	NA*
5	Afcons Infrastructure Limited	I-Sec, Nuvama, SBICAPS	NA*	NA*	NA*
6	Northern Arc Capital Limited	I-Sec	-7.15% [-5.80%]	NA*	NA*
7	Premier Energies Limited	I-Sec	+146.93% [+2.07%]	NA*	NA*
8	P N Gadgil Jewellers Limited	Nuvama	61.14% [-1.76%]	NA	NA
9	Allied Blenders and Distillers Limited	Nuvama	9.68% [3.43%]	21.28% [8.52%]	NA
10	Go Digit General Insurance Limited	Nuvama	22.83% [2.32%]	30.79% [7.54%]	16.25% [2.12%]
11	Popular Vehicles and Services Limited	Nuvama	-15.59% [1.51%]	-13.67% [7.55%]	-23.43% [16.22%]
12	Capital Small Finance Bank Limited	Nuvama	-25.25% [1.77%]	-26.09% [1.33%]	-31.44% [10.98%]
13	Godavari Biorefineries Limited	SBICAPS	-	-	-
14	Waaree Energies Limited	SBICAPS	-	-	-
15	Bajaj Housing Finance Limited	SBICAPS	+ 99.86% [-1.29%]	-	-
16	Ola Electric Mobility Limited	SBICAPS	+44.17% [+1.99%]	-2.11% [+0.48%]	-
17	Bansal Wire Industries Limited	SBICAPS	+37.40% [-0.85%]	+61.17% [+1.94%]	-
18	Stanley Lifestyles Limited	SBICAPS	+55.96% [+2.91%]	+31.29% [+7.77%]	-

Source: www.nseindia.com and www.bseindia.com

\* Data not available

Notes:

1. Data is sourced either from www.nseindia.com or www.bseindia.com, as per the designated stock exchange disclosed by the respective Issuer Company.
2. Similarly, benchmark index considered is "NIFTY 50" where NSE is the designated stock exchange and "S&P BSE SENSEX" where BSE is the designated stock exchange, as disclosed by the respective Issuer Company.
3. 30<sup>th</sup>, 90<sup>th</sup>, 180<sup>th</sup> calendar day from listed day have been taken as listing day plus 29, 89 and 179 calendar days, except wherever 30<sup>th</sup>, 90<sup>th</sup>, 180<sup>th</sup> calendar day is a holiday, in which case we have considered the closing data of the previous trading day.

For further details, please refer to "Other Regulatory and Statutory Disclosures - Price information of past issues handled by the BRLMs" on page 401 of the RHP.

<b>Name of Book Running Lead Manager ("BRLMs") and Members of the Syndicate</b>	<b>ICICI Securities Limited</b> <b>Tel:</b> +91 22 6807 7100 <b>E-mail:</b> surakshaipo@icicisecurities.com <b>Investor Grievance E-mail:</b> customercare@icicisecurities.com	<b>Nuvama Wealth Management Limited</b> <b>Tel:</b> +91 22 4009 4400 <b>E-mail:</b> suraksha.ipo@nuvama.com <b>Investor Grievance E-mail:</b> customerservice.mb@nuvama.com	<b>SBI Capital Markets Limited</b> <b>Tel:</b> +91 22 4006 9807 <b>E-mail:</b> suraksha.ipo@sbicaps.com <b>Investor Grievance E-mail:</b> investor.relations@sbicaps.com
<b>Name of Syndicate Member</b>	Nuvama Wealth Management Limited, SBICAP Securities Limited and Investec Capital Services (India) Private Limited		
<b>Name of Registrar to the Offer</b>	<b>KFin Technologies Limited</b> <b>Tel:</b> +91 40 6716 2222; <b>E-mail:</b> sdl.ipo@kfintech.com <b>Investor grievance E-mail:</b> einward.ris@kfintech.com		
<b>Name of Statutory Auditor</b>	M S K A & Associates, Chartered Accountants		
<b>Name of Credit Rating Agency and the rating or grading obtained, if any</b>	Not Applicable		
<b>Name of Debenture Trustee</b>	Not Applicable		
<b>Self-Certified Syndicate Banks</b>	<p>The banks registered with the SEBI, which offer the facility of ASBA services, (i) in relation to ASBA, where the Bid Amount will be blocked by authorizing an SCSB, a list of which is available on the website of SEBI at <a href="http://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&amp;intmId=34">www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&amp;intmId=34</a> and updated from time to time and at such other websites as may be prescribed by SEBI from time to time, (ii) in relation to UPI Bidders using the UPI Mechanism, a list of which is available on the website of SEBI at <a href="http://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&amp;intmId=40">www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&amp;intmId=40</a> or such other website as updated from time to time.</p> <p>Applications through the UPI Mechanism in the Offer can be made only through the SCSBs Mobile Applications. A list of SCSBs and mobile application, which are live for applying in public issues using UPI Mechanism is provided as Annexure 'A' to the SEBI circular no. SEBI/HO/CFD/DIL2/CIR/P/2019/85 dated July 26, 2019. The list is available on the website of SEBI at <a href="http://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&amp;intmId=43">www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&amp;intmId=43</a> and updated from time to time and at such other websites as may be prescribed by SEBI from time to time.</p>		
<b>SCSBs eligible as Issuer Banks for UPI and mobile applications enabled for UPI Mechanism</b>	<p>In accordance with SEBI RTA Master Circular, SEBI Circular No. SEBI/HO/CFD/DIL2/CIR/P/2019/76 dated June 28, 2019, SEBI Circular No. SEBI/HO/CFD/DIL2/CIR/P/2019/85 dated July 26, 2019, and SEBI Circular No. SEBI/HO/CFD/DIL2/CIR/P/2022/45 dated April 5, 2022, Retail Individual Investors Bidding using the UPI Mechanism may only apply through the SCSBs and Mobile Applications using the UPI handles specified on the website of the SEBI (<a href="https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&amp;intmId=40">https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&amp;intmId=40</a>) and (<a href="https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&amp;intmId=43">https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&amp;intmId=43</a>) respectively, as updated from time to time. A list of SCSBs and Mobile Applications, which are live for applying in public issues using UPI mechanism is provided as 'Annexure A' for the SEBI circular number SEBI/HO/CFD/DIL2/CIR/P/2019/85 dated July 26, 2019.</p>		

# IN THE NATURE OF ABRIDGED PROSPECTUS - MEMORANDUM CONTAINING SALIENT FEATURES OF THE RED HERRING PROSPECTUS

<b>Syndicate SCSB Branches</b>	In relation to Bids (other than Bids by Anchor Investors and RIIs) submitted to a member of the Syndicate, the list of branches of the SCSBs at the Specified Locations named by the respective SCSBs to receive deposits of Bid cum Application Forms from the members of the Syndicate is available on the website of the SEBI at <a href="http://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognised=yes&amp;intmId=35">http://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognised=yes&amp;intmId=35</a> , which may be and updated from time to time or any such other website as may be prescribed by SEBI from time to time. For more information on such branches collecting Bid cum Application Forms from the Syndicate at Specified Locations, see the website of the SEBI at <a href="http://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognised=yes&amp;intmId=35">http://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognised=yes&amp;intmId=35</a> or any such other website as may be prescribed by SEBI from time to time.
<b>Registered Brokers</b>	The list of the Registered Brokers, eligible to accept ASBA forms, including details such as postal address, telephone number, and email address, is provided on the websites of BSE and NSE at <a href="http://www.bseindia.com/Markets/PublicIssues/brokercentres_new.aspx?expandable=3">http://www.bseindia.com/Markets/PublicIssues/brokercentres_new.aspx?expandable=3</a> and <a href="http://www.nseindia.com/products/content/equities/ipo/ipo_mem_terminal.htm">http://www.nseindia.com/products/content/equities/ipo/ipo_mem_terminal.htm</a> , respectively, or such other websites as updated from time to time.
<b>Details regarding website address(es)/ link(s) from which the investor can obtain a list of RTAs, CDPs and stock brokers who can accept applications from investors, as applicable</b>	The list of the RTAs eligible to accept ASBA Forms at the Designated RTA Locations, including details such as address, telephone number, and e-mail address, are provided on the websites of BSE and NSE at <a href="http://www.bseindia.com/Static/Markets/PublicIssues/RtaDp.aspx?expandable=6">http://www.bseindia.com/Static/Markets/PublicIssues/RtaDp.aspx?expandable=6</a> and <a href="http://www.nseindia.com/products/content/equities/ipo/ipo_mem_terminal.htm">http://www.nseindia.com/products/content/equities/ipo/ipo_mem_terminal.htm</a> , respectively, or such other websites as updated from time to time. The list of the CDPs eligible to accept ASBA Forms at the Designated CDP Locations, including details such as name and contact details, are provided on the websites of BSE and NSE at <a href="http://www.bseindia.com/Static/Markets/PublicIssues/RtaDp.aspx?expandable=6">http://www.bseindia.com/Static/Markets/PublicIssues/RtaDp.aspx?expandable=6</a> and <a href="http://www.nseindia.com/products/content/equities/ipo/ipo_mem_terminal.htm">http://www.nseindia.com/products/content/equities/ipo/ipo_mem_terminal.htm</a> , respectively, or such other websites as updated from time to time. For further details, see “Offer Procedure” on page 418 of the RHP.

## PROMOTERS OF OUR COMPANY

Sr. No.	Name	Individual/ Corporate	Experience & Educational Qualification/ Corporate Information
1	Dr. Somnath Chatterjee	Individual	He obtained his bachelor's degree in medicine and surgery from the University of Calcutta in 1985 and is registered with the West Bengal Medical Council. He has been associated with our Company and Suraksha Diagnostic & Eye Centre Private Limited since their incorporation and has more than 32 years of experience in the field of medical and diagnostics business.
2	Ritu Mittal	Individual	She has cleared the examination for a bachelor's degree in commerce from the University of Calcutta in 1996. She has more than 28 years of experience in the field of medical and diagnostics business. Prior to joining our Company, she was associated with Suraksha Diagnostic & Eye Centre Private Limited.
3	Satish Kumar Verma	Individual	He obtained his bachelor's degree in mechanical engineering from Punjabi University in 1969 and post-graduate diploma in engineering from Punjab University in 1971. He has more than 40 years of experience in management. He is currently a director with Kanika Audio Visuals Private Limited.

For details in respect of our Promoters, please see the section titled “Our Promoters and Promoter Group” beginning on page 286 of the RHP.

## OUR BUSINESS OVERVIEW AND STRATEGY

**Company Overview:** We offer a one-stop integrated solution for pathology and radiology testing, and medical consultation services to our customers through our extensive operational network, consisting of our flagship central reference laboratory, 8 satellite laboratories (co-located with our diagnostic centers) and 215 customer touchpoints which include 49 diagnostic centres, and 166 sample collection centres (primarily franchised), as of June 30, 2024 across the states of West Bengal, Bihar, Assam, and Meghalaya. For details of our operational network, see “- Our Operational Network” on page 232 of the RHP. Our central reference laboratory has an accreditation from the College of American Pathologists, 3 of our laboratories hold National Accreditation Board for Testing and Calibration Laboratories (“NABL”) and 3 of our advanced diagnostic centres hold National Accreditation Board for Hospitals & Healthcare Providers (“NABH”) accreditations. As of June 30, 2024, 44 of our diagnostic centres also housed 126 polyclinic chambers hosting 750+ specialized doctors for patient convenience. During the three months period ended 2024, we conducted approximately 1.58 million tests serving approximately 0.28 million patients and derived 95.34% of our revenue from operations from our core geography, Kolkata and the rest of West Bengal. During the Fiscal 2024, we conducted approximately 5.98 million tests serving approximately 1.14 million patients and derived 95.48% of our revenue from operations from our core geography, Kolkata and the rest of West Bengal. Our radiology equipment consists of 24 CT and 13 MRI machines. As of June 30, 2024, our operational network comprises a diagnostic center network of (i) 13 hub centres, which are equipped to conduct all pathology sample collections, basic and advanced radiology tests; and (ii) our ‘spoke’ diagnostic centres which include our 11 medium centers, 23 small centres and 2 centres operated under public-private partnership (“PPP”) model, which 345 are equipped to conduct all pathology sample collection and certain basic radiology tests, further supported by 166 sample collection centres (primarily franchised); and a laboratory network of (i) our flagship central reference laboratory; and (ii) 8 satellite laboratories which are co-located with certain hub centres. For details, see “- Operational Network” on page 232 of the RHP. Our Company's market share in the diagnostics services market in Eastern India was 1.15% to 1.30% in Fiscal 2024 whereas peers such as Dr. Lal Pathlabs Limited have a market share of 5.30% to 5.70% in its major market i.e north India and Vijaya Diagnostic Centre Limited, a market share of 2.20% to 2.50% in its major market, i.e. South India. (Source: CRISIL Report, as replicated on page 201 of the RHP) We offered a comprehensive range of 2,300+ tests that cover a range of specialties and disciplines, as of June 30, 2024. Our diagnostic test menu included (a) 788 routine pathology tests ranging from basic biochemistry and hematology to 664 specialized pathology tests such as advanced biochemistry, histopathology, and molecular pathology, and (b) 766 basic/intermediate radiology tests ranging from basic x-rays, ultrasonography (“USG”), and computerized tomography (“CT”) scans to 119 advanced radiology tests such as magnetic resonance imaging (“MRI”) scans and specialized CT scans, as of June 30, 2024. The table below depicts the revenue contribution of our services offered for the periods indicated:

Particulars	Three months period ended June 2024		Fiscal 2024		Fiscal 2023		Fiscal 2022	
	Revenue (in ₹ million)	% of Total Revenue from Operations (in %)	Revenue (in ₹ million)	% of Total Revenue from Operations (in %)	Revenue (in ₹ million)	% of Total Revenue from Operations (in %)	Revenue (in ₹ million)	% of Total Revenue from Operations (in %)
Radiology	282.52	46.52	1,006.72	46.03	841.31	44.25	697.32	31.24
Pathology	302.14	49.75	1,165.81	53.30	1,024.57	53.89	797.00	35.71
Doctor Consultation	22.45	3.70	10.62	0.49	-	-	-	-
Covid tests	0.21	0.03	3.94	0.18	35.46	1.87	737.60	33.05
<b>Total</b>	<b>607.32</b>	<b>100.00</b>	<b>2,187.09</b>	<b>100.00</b>	<b>1,901.34</b>	<b>100.00</b>	<b>2,231.93</b>	<b>100.00</b>

\* Doctor Consultation services were offered but no revenue was generated for the relevant periods.



# IN THE NATURE OF ABRIDGED PROSPECTUS - MEMORANDUM CONTAINING SALIENT FEATURES OF THE RED HERRING PROSPECTUS

## Key Performance Indicators:


KPIs	Unit	June 30, 2024	Fiscal 2024	Fiscal 2023	Fiscal 2022
<b>Financial</b>					
Revenue from operations <sup>1</sup>	(₹ in million)	607.32	2,187.09	1,901.34	2,231.93
Restated profit for the year/period <sup>2</sup>	(₹ in million)	76.67	231.27	60.65	208.24
EBITDA <sup>3</sup>	(₹ in million)	217.21	736.18	474.79	652.53
EBITDA Margin <sup>4</sup>	%	35.77	33.66	24.97	29.24
Return on Equity <sup>5</sup>	%	4.33 <sup>#</sup>	14.09	4.32	15.38
Return on Capital Employed <sup>6</sup>	%	6.32 <sup>#</sup>	21.46	9.05	23.11
Net debt/equity <sup>7</sup>	-	0.16	0.20	0.27	0.37
Average revenue per patient <sup>8</sup>	(₹)	2,146.01	1,922.44	1,711.58	1,317.81
Average revenue per centre <sup>9</sup>	(₹ in million)	12.39	45.56	44.22	54.44
EBITDA per patient <sup>10</sup>	(₹)	767.53	647.10	427.40	385.28
<b>Operational</b>					
Number of tests per patient <sup>11</sup>	Unit	5.58	5.26	4.65	2.95
Revenue generated from East India	%	100	100	100	100
B2C revenues	%	93.48	93.83	96.01	95.56
B2B revenues	%	6.52	6.17	3.99	4.44
Revenue from radiology	%	46.52	46.03	44.25	31.24
Revenue from pathology	%	49.75	53.30	53.89	35.71
Revenue from COVID-19 tests	%	0.03	0.18	1.86	33.05
Number of Centres	Unit	49	48	43	41
Number of Laboratories	Unit	9	9	8	7
Number of NABL accredited labs	Unit	3	3	3	3
Number of patients served	million	0.28	1.14	1.11	1.69
Number of patients served per centre	Unit	5,776	23,701	25,834	41,309
Number of tests performed	million	1.58	5.98	5.17	4.99
Number of Small centres <sup>12</sup>	Unit	23	23	19	18
Number of Medium centres <sup>13</sup>	Unit	11	10	10	10
Number of Large centres <sup>14</sup>	Unit	13	13	12	12
Number of public private partnerships <sup>15</sup>	Unit	2	2	2	1
Customer touch points					
- Number of Centres	Unit	49	48	43	41
- Collection Centres	Unit	161	142	123	111
- Company Owned Collection Centres	Unit	5	4	8	2
Total	Unit	215	194	174	154
Number of doctors (radiologists, pathologists and microbiologists)	Unit	278	283	234	186
- Radiologists	Unit	255	260	209	156
- Pathologists	Unit	19	19	22	27
- Microbiologists	Unit	4	4	3	3
Number of CT machines	Unit	24	24	23	23
Number of MRI machines	Unit	13	13	12	12



Notes:

- Revenue from operations = Revenue from operations
- Restated profit for the year/period = Profit after Tax
- EBITDA is calculated as restated profit for the year/period plus Exceptional items, tax expenses, finance costs, depreciation, and amortization expense
- EBITDA Margin is the percentage of EBITDA divided by revenue from operations
- Return on equity is calculated as restated profit for the year/period attributable to owners of the parent divided by average equity attributable to owners of the parent
- Return on capital employed is calculated as a percentage of EBIT (i.e., calculated as restated profit for the year/period before tax expenses and finance costs) divided by average capital employed (i.e., total equity plus total borrowings, lease liabilities, deferred tax liabilities excluding right of use assets and other intangible assets and intangible assets under development).
- Net Debt to equity is calculated as net debt (i.e., total borrowings and lease liabilities less cash and bank balances) divided by total equity
- Average revenue per patient is calculated as revenue from operations divided by the number of patients served
- Average revenue per centre is calculated as Revenue from operations divided by number of centers
- EBITDA per Patient is calculated as EBITDA divided by the number of patients served
- Number of tests per patient visit is calculated as number of tests divided by number of patients served
- Small centres means centres whose offerings include USG, X-ray, cardio, sample collection
- Medium centres means centres whose offerings include CT scan, USG, X-ray, cardio, sample collection
- Large centres means centres whose offerings include MRI, CT scan, USG, X-ray, cardio, sample collection.
- Our Company currently operates 2 centres under public-private partnership model: (i) in Shillong through our Subsidiary, Suraksha Salvia LLP that provides diagnostic services, and (ii) at Kolkata, West Bengal, through partnership between a medical college and hospital and our Promoter Group entity and Group Company, Suraksha Diagnostic & Eye Centre Private Limited, which is managed by our Company that provides diagnostic services.

#Not annualised

**Geographies served:** Kolkata and the rest of West Bengal

**Intellectual Property:** The trademarks of our primary operating brand ‘’ (Trademark (TM) Registration No.: 1257149 under Class:42) and ‘**Suraksha**’ (Trademark (TM) Registration No.: 2684022 under Class:44) is currently registered in the name of our Group Company, Suraksha Diagnostic & Eye Centre Private Limited (“SDECPL”). Pursuant to a deed of assignment dated April 1, 2024, SDECPL has undertaken to assign the rights to our Company. The transfer of registration of the trademarks are currently ongoing. We have also filed applications for the registration of our word trademark

‘Suraksha’ under class 42 and 44 of the Trade Mark Act, 1999, our corporate logo ‘’, under class 42 and 44 of the Trade Mark Act, 1999 and our logo ‘’ under class 42 and 44 of the Trade Mark Act, 1999’, which are currently pending.

# IN THE NATURE OF ABRIDGED PROSPECTUS - MEMORANDUM CONTAINING SALIENT FEATURES OF THE RED HERRING PROSPECTUS

**Manufacturing Plant, if any:** Not Applicable.

**Employee Strength:** As of June 30, 2024, we have 1,506 permanent employees and contractual employees/consultants on retainer basis, including 23 laboratory doctors, 255 radiologists/other reporting doctors and 529 technical staff. Our laboratories are managed by qualified scientific staff and supervised by a team of pathologists with specializations in relevant fields of laboratory medicine.

For further information, see “Our Business – Employees” on page 244 of the RHP.

BOARD OF DIRECTORS				
Sr. No.	Name	Designation	Experience & Educational Qualification	Directorships in other companies
1.	Dr. Somnath Chatterjee	Chairman and Joint Managing Director	He obtained his bachelor's degree in medicine and surgery from the University of Calcutta in 1985 and is registered with the West Bengal Medical Council. He has been associated with our Company and Suraksha Diagnostic & Eye Centre Private Limited since their incorporation and has more than 32 years of experience in the field of medical and diagnostics business.	<i>Indian Companies:</i> • Suraksha Radiology Private Limited • Suraksha Diagnostic & Eye Centre Private Limited • Tinni Investments Limited <i>Foreign Companies</i> Nil
2.	Ritu Mittal	Joint Managing Director and Chief Executive Officer	She has cleared the examination for a bachelor's degree in commerce from the University of Calcutta in 1996. She has more than 28 years of experience in the field of medical and diagnostics business. Prior to joining our Company, she was associated with Suraksha Diagnostic & Eye Centre Private Limited.	<i>Indian Companies:</i> • ERC India Limited • Manila Enclave Private Limited • Rama Special Steels Private Limited • Suraksha Radiology Private Limited <i>Foreign Companies:</i> Nil
3.	Satish Kumar Verma	Non-Executive, Non-Independent Director	He obtained his bachelor's degree in mechanical engineering from Punjabi University in 1969 and post-graduate diploma in engineering from Punjab University in 1971. He has more than 40 years of experience in management. He is currently a director with Kanika Audio Visuals Private Limited.	<i>Indian Companies:</i> • Akanksha Viniyog Limited • Kanika Audio Visuals Private Limited • Senao International Limited <i>Foreign Companies:</i> Nil
4.	Arun Sadhanandham	Non-Executive, Non-Independent (Nominee) Director*	He obtained his bachelor's degree of engineering from the Anna University, Chennai and a post graduate diploma in management from Indian Institute of Management, Bengaluru. He has more than 13 years of work experience. He is currently an Executive Director with OrbiMed Advisors India Private Limited and prior to joining OrbiMed Advisors India Private Limited, was associated with Kotak Mahindra Capital Company Limited, o3 Capital Global Advisory Private Limited and Mu Sigma Business Solution Private Limited.	<i>Indian Companies:</i> • Blue Sapphire Healthcare Private Limited • Entero Healthcare Solutions Limited • LifeWell Diagnostics Private Limited <i>Foreign Companies:</i> Nil
5.	Pradip Kumar Dutta	Independent Director	He obtained his bachelor's degree in technology in electronics and electrical communication engineering from Indian Institute of Technology Kharagpur in 1981, a master's degree in science from the University of Maryland in 1983 and a doctorate in philosophy from the University of Maryland in 1988. During his time at University of Maryland, he also held a National Bureau of Standards Graduate Research Fellowship. He has several years of work experience. Prior to joining our Company, he was associated as vice president – engineering of Synopsys (India) Private Limited and is currently advisor to the board at Simyog Technology. He was conferred the distinguished alumnus award by Indian Institute of Technology Kharagpur in 2011.	<i>Indian companies</i> Nil <i>Foreign companies</i> Nil
6.	Ishani Ray	Independent Director	She obtained her bachelor's degree in commerce and master's degree in commerce from the University of Calcutta in 1986 and 1989 respectively. She has been an associate of the Institute of Chartered Accountants of India and is eligible to practice as a chartered accountant since 1991. She has more than 27 years of experience in finance. Prior to joining our Company, she was associated with Khadim India Limited as the chief financial officer and chief executive officer, and with Saregama India Limited as manager – finance and taxation.	<i>Indian Companies:</i> • ABC India Limited • Gloster Limited • Yellow Hat Consultants Private Limited • Rahee Infratech Limited <i>Foreign Companies:</i> Nil
7.	Siddhartha Roy	Independent Director	He obtained his bachelor's degree in law from Calcutta University in 1985. He is also a member of the Institute of Company Secretaries of India since 1984. He has over 39 years of work experience. Prior to joining our Company, he worked at Warren Tea Limited for over 23 years where at the time of retirement from the services of the company, he was President (Legal) and Company Secretary. Further, he was associated with other organizations such as KHSI Industries Limited, Brooke Bond Lipton India Limited and Ityadi Prakasani Limited. He is currently an independent director on the board of Amgoorie India Limited.	<i>Indian Companies:</i> • Amgoorie India Limited <i>Foreign Companies</i> Nil
8.	Dharam Chand Dharewa	Independent Director	He obtained his bachelor's degree in commerce from G.D. Binani Mahavidyalaya in 1979. He is also a practicing chartered accountant since 1987. He has over 30 years of experience. He is currently an independent director on the boards of Singhi Capital Finance Private Limited and Warren Tea Limited.	<i>Indian Companies:</i> • Singhi Capital Finance Private Limited • Warren Tea Limited <i>Foreign Companies</i> Nil

For further details in relation to our Board of Directors, see “Our Management” beginning on page 265 of the RHP.



**OBJECTS OF THE OFFER**

The objects of the Offer are to (i) carry out the Offer for Sale of up to 19,189,330 Equity Shares of face value ₹ 2 each aggregating to ₹ [●] million by the Selling Shareholders; and (ii) achieve the benefits of listing the Equity Shares on the Stock Exchanges. Further, our Company expects that the proposed listing of its Equity Shares will enhance our visibility and brand image as well as provide a public market for the Equity Shares in India.

**Utilisation of the Offer Proceeds**

Our Company will not receive any proceeds from the Offer (“Offer Proceeds”) and all such proceeds (net of any Offer related expenses to be borne by the Selling Shareholders) will go to the Selling Shareholders, in proportion to the Offered Shares sold by the respective Selling Shareholder as part of the Offer.

**Details and reasons for non-deployment or delay in deployment of proceeds or changes in utilisation of issue proceeds of past public offers / rights issues, if any, of our Company in the preceding 10 years:** Not Applicable.

**Terms of Issuance of Convertible Security, if any:** Not applicable

**Name of Monitoring Agency:** As the Offer is an offer for sale of Equity Shares, our Company is not required to appoint a monitoring agency for this Offer.

**Shareholding Pattern as on the date of the RHP:**

Category of shareholder	Number of fully paid-up Equity Shares held	Shareholding as a % of total number of shares
Promoters and Promoter Group	31,802,034	61.07
Public	-	0.00
Non-Promoter-Non-Public	2,02,78,724	38.93
OrbiMed Asia II Mauritius Limited	17,367,448	33.35
Munna Lal Kejriwal	1,106,062	2.12
Sandeep Kejriwal	4,56,875	0.88
Santosh Kumar Kejriwal	1,348,339	2.59
<b>Total</b>	<b>52,080,758</b>	<b>100.00</b>

**Number/amount of equity shares proposed to be sold by selling shareholders:** Up to 19,189,330 Equity Shares of face value ₹2 each

**SUMMARY OF SELECT FINANCIAL INFORMATION DERIVED FROM OUR RESTATED CONSOLIDATED FINANCIAL INFORMATION**

The details of certain financial information as set out under the SEBI ICDR Regulations as at and for the three month period ended June 30, 2024 and financial years ended March 31, 2024, 2023 and 2022 derived from the Restated Consolidated Financial Information are as follows:

(₹ in million, except per share data)

Particulars	As at and for the three month period ended June 30, 2024	As at and for the Year ended March 31, 2024	As at and for the Year ended March 31, 2023	As at and for the Year ended March 31, 2022
Equity share capital	86.25	69.00	69.00	69.00
Net Worth <sup>1</sup>	1,870.50	1,794.08	1,559.26	1,458.42
Revenue from operations	607.32	2,187.09	1,901.34	2,231.93
Total income	618.49	2,222.60	1,936.87	2,257.68
Profit after tax	76.67	231.27	60.65	208.24
<b>Restated earnings per Equity Share<sup>2</sup></b>	<b>1.49*</b>	<b>4.43</b>	<b>1.22</b>	<b>3.91</b>
- Basic per Equity Share with a nominal value of ₹2 (in ₹)	1.49*	4.43	1.22	3.91
- Diluted earnings per Equity Share with a nominal value of ₹2 each (in ₹)	1.49*	4.43	1.22	3.91
NAV per equity share (in ₹) <sup>3</sup>	35.09	33.66	29.25	27.36
Total borrowings	75.66	86.37	140.07	190.27

\*Not annualized.

Notes:

1. “Net worth” means the aggregate value of paid-up equity share capital and other equity created out of the profits, securities premium account and debit or credit balance of profit and loss account which is attributable to the owners of the parent, derived from the Restated Consolidated Financial Information.
2. Earning per share (Basic & Diluted) is calculated by dividing profit for the year attributable to the owners of the parent by dividing average number of equity shares outstanding during the year and potential additional equity shares outstanding during the year.
3. Net asset value per Equity Share (in ₹) = Net asset value per Equity Share has been calculated as restated net worth as of the end of the relevant year divided by the weighted average number of potential equity shares during the year.
4. In accordance with the Restated Consolidated Financial Statements, the basic and diluted EPS was calculated assuming the conversion ratio of 1 CCPS into 62.5 Equity shares. However, subsequently on November 13, 2024 the CCPS was converted to equity shares in the ratio 1 CCPS for 54.99 equity shares.

For further details, see “Financial Information – Restated Consolidated Financial Information” on page 292 of the RHP.

**INTERNAL RISK FACTORS**

We provide a comprehensive suite of products. If we fail to develop new products and innovate our products, our business, operating results, financial performance, cash flows and prospects may be materially and adversely affected.

1. 95.48% of our Revenue from Operations in Fiscal 2024 was generated from West Bengal, and any loss of business in such region could have an adverse effect on our business, results of operations and financial condition.
2. The securities of certain of our Promoter Group members have been suspended from trading on a recognized stock exchange in the past. We cannot assure you that there will be no such instances in the future which may adversely affect our operations, reputation and ability to raise capital through further public issue of securities.
3. The diagnostics industry in India is highly competitive and our inability to compete effectively from other healthcare service providers may adversely affect our business, results of operations and financial condition. Further, as of Financial Year 2024, the market share of our Company in our major market which is East India is 1.15-1.30%.
4. The B2B segment contributed to 6.17% of our Revenue from Operations in Fiscal 2024 and any non-renewal or cancellation of our arrangements with our institutional customers, including hospitals, and Public-Private Partnership contracts may adversely affect our business, results of operations and financial condition.
5. Our Statutory Auditors have included certain emphasis of matters, and audit qualifications matters prescribed in the audit reports of our Company for Fiscals 2023 and 2024.

For further details, see “Risk Factors” beginning on page 36 of the RHP.

**SUMMARY OF OUTSTANDING LITIGATIONS, CLAIMS AND REGULATORY ACTION**

- A. A summary of outstanding litigation involving our Company, Directors, Promoters, and Subsidiaries as of the date of the Red Herring Prospectus, as also disclosed in “*Outstanding Litigation and Material Developments*” on page 381 of the RHP, in terms of the SEBI ICDR Regulations and the materiality policy adopted by our Board pursuant to a resolution dated July 20, 2024, is provided below:-

Name of Entity	Criminal Proceedings	Tax Proceedings	Statutory or Regulatory Proceedings	Disciplinary actions by SEBI or Stock Exchanges against our Promoters	Material civil litigations <sup>^</sup>	Aggregate amount involved* (in ₹ million)
<b>Company</b>						
By the Company	1	Nil	Nil	NA	2	31.35
Against our Company**	Nil	1	4	NA	2	9.00
<b>Directors</b>						
By our Directors	Nil	Nil	Nil	NA	Nil	Nil
Against our Directors	Nil	1	Nil	NA	Nil	0.22
<b>Promoters<sup>\$</sup></b>						
By our Promoters	Nil	Nil	Nil	NA	Nil	Nil
Against our Promoters	Nil	1	Nil	Nil	Nil	0.22
<b>Subsidiaries</b>						
By the Subsidiaries	Nil	Nil	Nil	NA	Nil	Nil
Against the Subsidiaries	Nil	Nil	Nil	NA	1	NA

\* To the extent quantifiable.

\*\* The court records indicate that one of the cases against the Company is dismissed, however we await the copy of the order passed. For more details, please see “Material Civil litigation initiated against our Company” on page 383 of the Red Herring Prospectus.

<sup>^</sup> Determined in accordance with the Materiality Policy

<sup>\$</sup> As on the date of the Red Herring Prospectus, outstanding litigation involving our Promoters also reflect outstanding litigation involving our Directors as each of our Promoters are also Directors of the Company.

Except as disclosed in the “Material Civil litigation initiated against our Company” on page 383 of the RHP, none of our Group Companies are currently party to any pending litigations which would have a material impact on our Company.

For further details of the outstanding litigation proceedings involving our Company, Subsidiaries, Directors, Promoters and our Group Company, please refer to the section titled “*Outstanding Litigation and Other Material Developments*” beginning on page 381 of the RHP.

- B. Brief details of top 5 material outstanding litigation / legal proceedings initiated against the Company and amount involved:

Sr. No.	Particulars	Current Status	Amount involved (in ₹ million)
1.	A consumer application dated August 9, 2018 was filed before the Consumer Dispute Redressal Commission, West Bengal wherein the applicant had purchased a HIV pathological test from our Company which tested positive for HIV I, after which she purchased another test from a different pathological lab which tested negative.	The matter is currently pending.	9.00
2.	The Company has filed compounding applications dated July 20, 2024 with the Registrar of Companies, Kolkata at West Bengal (“ROC”) under Section 621 of erstwhile Companies Act, 1956, and Section 441 of the Companies Act, 2013, for compounding of the offences related to violation of section 383A of the Companies Act, 1956, and section 203 of the Companies Act, 2013, for failure to appoint a whole-time Company Secretary.	The Company has submitted part penalty. The matter is currently pending for adjudication for time period July 1, 2017 to February 2, 2019 due to decriminalisation of the offence.	NA
3.	A writ petition under Article 226 of the Constitution of India dated September, 2024 was filed before the High Court at Calcutta by Wipro GE Healthcare Private Limited against the State of West Bengal and others including the Company, Suraksha Radiology Private Limited (our Subsidiary), Suraksha Diagnostic Limited, Suraksha Diagnostic & Eye Centre Private Limited (our Group Company), etc. The Petitioner has prayed for a writ of mandamus and certiorari, alleging a violation of Clause 11 of the General Financial Rules, 2017.	The court records indicate that this case has been dismissed, however the Company awaits the copy of the order passed in this regard.	NA
4.	Inspector under the West Bengal Shops And Establishment Act 1963 has filed a complaint dated March 18, 2019, before Additional Chief Judicial Magistrate, Barrackpore, West Bengal against our Company for violation of rules 11(1), 30, 48 and 53 of West Bengal Shops And Establishment Act 1963, and sections 16(3) and 18 of West Bengal Shops And Establishment Act 1963.	The matter is pending and listed for hearing.	NA
5.	Inspector under Contract Labour (Regulation & Abolition) Act, 1970, State of West Bengal filed a complaint dated March 2, 2019, before Additional Chief Judicial Magistrate, Barrackpore, West Bengal against the Company for alleged violation of, <i>inter alia</i> , sections 29(1), 29(2) and 35(2)(n) of Contract Labour (Regulation & Abolition) Act, 1970 and rules 74, 81 and 82(2) of Contract Labour (Regulation & Abolition) Central Rules, 1971.	The matter is currently pending and listed for hearing.	NA

- C. Disciplinary action taken by SEBI or stock exchanges against the Promoters in last 5 financial years including outstanding action, if any: Nil.

- D. Brief details of outstanding criminal proceedings against the Promoters: Nil

For further details of the outstanding litigation proceedings, see “*Outstanding Litigation and Material Developments*” on page 381 of the RHP.

**ANY OTHER IMPORTANT INFORMATION AS PER BOOK RUNNING LEAD MANAGER/COMPANY - NIL**

**DECLARATION BY OUR COMPANY**

We hereby certify and declare that all relevant provisions of the Companies Act, 2013 and the rules, regulations and guidelines issued by the Government of India and the rules, regulations and guidelines issued by the Securities and Exchange Board of India, established under Section 3 of the Securities and Exchange Board of India Act, 1992, as amended as the case may be, have been complied with and no statement made in the Red Herring Prospectus is contrary to the provisions of the Companies Act, 2013, the Securities Contracts (Regulation) Act, 1956, the Securities Contracts (Regulation) Rules, 1957, the Securities and Exchange Board of India Act, 1992, each as amended and the rules made and the guidelines and regulations issued thereunder, as the case may be. We further certify that all statements in the Red Herring Prospectus are true and correct.

**DECLARATION BY THE SELLING SHAREHOLDERS**

Each of the Selling Shareholders hereby confirm that all statements, and undertakings specifically made or confirmed by them in the Red Herring Prospectus in relation to them, as one of the Selling Shareholder and my portion of the Offered Shares, are true and correct. The Selling Shareholders assume no responsibility for any other statements, disclosures and undertakings, including, any of the statements, disclosures or undertakings made or confirmed by or relating to the Company or any other Selling Shareholder(s) or any other person(s) in the Red Herring Prospectus.

# IN THE NATURE OF ABRIDGED PROSPECTUS - MEMORANDUM CONTAINING SALIENT FEATURES OF THE RHP

## BIDDER'S UNDERTAKING AND CONFIRMATION FOR BID REVISION FORM

I/We (on behalf of joint Bidders, if any) confirm that the Acknowledgement Slip for my/our Bids is enclosed for the revisions which are being requested. I/We agree to be bound by all the terms & conditions mentioned in the Bid cum Application Form submitted earlier by me/us. I/We (on behalf of joint Bidders, if any) authorise you to reject this Bid Revision Form, in case any of the details of my/our existing Bids as appearing on the electronic book building system do not tally with the details given in this Bid Revision Form.

## INSTRUCTIONS FOR FILLING UP THE BID REVISION FORM

- Name of sole/ first Bidder should be exactly the same as it appears in the Depository records. In case of joint Bids, the Bid cum Application Form should contain only the name of the first Bidder whose name should also appear as the first holder of the beneficiary account held in joint names. The Bid means an 'indication to make an offer' and not 'an offer'.
- Please ensure that the Bid options provided are in the same order as that provided in the Bid cum Application Form submitted earlier.
- In case there is no change in the particular Bid option, please write "NO CHANGE". In case you want to cancel the Bid option, please write "CANCELLED".
- Total Bid Amount payable must be calculated for the highest of three options, at Bid Price. Total Bid Amount to be paid must be calculated net of total amount paid at the time of submission of Bid cum Application Form. Bidders, please ensure that your bank has notified an SCSB Branch in the city where the Bid cum Application Form is being submitted.
- Revision of Bids in case of Revision of Price Band:** In case of an upward revision in the Price Band, Retail Individual Bidders who had Bid at Cut-off Price could either (i) revise their Bid or (ii) shall make additional payment based on the cap of the revised Price Band (such that the total amount i.e., original Bid Amount plus additional payment) does not exceed ₹ 200,000 if the Bidder wants to continue to Bid at Cut-off Price), with the SCSBs/ Members of the Syndicate/Registered Brokers/RTA/CDPs to whom the original Bid was submitted. In case the total amount (i.e., original Bid Amount plus additional payment) exceeds ₹ 200,000, the Bid will be considered for allocation under the Non-Institutional Portion in terms of the RHP or the Preliminary Offering Memorandum, as applicable. If, however, the Bidder does not either revise the Bid or make additional payment and the Offer Price is higher than the Cap Price prior to revision, the number of Equity Shares Bid for, shall be adjusted downwards for the purpose of Allotment, such that no additional amount would be required to be blocked and the Bidder is deemed to have approved such revised Bid at Cut-off Price. In case of a downward revision in the Price Band, announced as above, Retail Individual Bidders who have bid at Cut-off Price, could either revise their Bid or the excess amount blocked at the time of bidding would be unblocked from the ASBA Account after the Allotment is finalised.
- The sole Bidder/ first Bidder is required to sign the Bid cum Application Form/ Revision Form. Thumb impressions and signatures other than in the languages specified in the Eighth Schedule to the Constitution of India must be attested by a Magistrate or a Notary Public or a Special Executive Magistrate under official seal. Applicants should specify only his/her ASBA bank account or UPI ID linked with his/her own bank account in case of sole Bidder and ASBA bank account or UPI ID linked with the bank account of first Bidder in case of joint Bidder, in the application form. If the first Bidder is not the account holder, ensure that the Bid cum Application Form is signed by the ASBA Account holder. Signature of the ASBA Account holder is mandatory.
- Please note that application made using third party UPI ID or third party ASBA Bank A/c are liable to be rejected.
  - QIBs cannot use UPI Mechanism to apply. UPI Bidders applying up to ₹ 500,000 can apply through UPI mode as per NPCI vide circular reference no. NPCI/UPI/OC No. 127/2021-22 dated December 09, 2021 read with SEBI circular no. SEBI/HO/CFD/DIL2/CIR/P/2022/45 dated April 5, 2022.
  - For Retail Individual Bidders (RIBs) and Non-Institutional Bidders with Application size up to Rs. 500,000 ("UPI Bidders") bidding through the UPI Mechanism:**
    - Please ensure that your bank is offering UPI facility for public offers.
    - Please mention UPI ID clearly in CAPITAL LETTERS only.
    - Ensure that the: (a) bank where the bank account linked to their UPI ID is maintained; and (b) Bidders Bidding using the UPI Mechanism may apply through the SCSBs and mobile applications whose names appears on the website of the SEBI (<https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&intmid=40>) and (<https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&intmid=43>) respectively, as updated from time to time.
    - Eligible NRIs applying in the Offer through the UPI Mechanism, are advised to enquire with the relevant bank where their account is UPI linked prior to submitting their Bid cum Application Form.
    - UPI ID cannot exceed 45 characters.
    - Please ensure that you are using your UPI ID only and not the UPI ID of any third party.
    - UPI Bidders Bidding using the UPI Mechanism shall ensure that details of the Bid are reviewed and verified by opening the attachment in the UPI Mandate Request and then proceed to authorise the UPI Mandate Request using his/her UPI PIN. For further details, see "Offer Procedure" on page 418 of the RHP.
- Other Instructions:** a. revision to Bids must be made only in the prescribed Revision Form, as applicable; b. Revision Form must be completed in full, in BLOCK LETTERS in ENGLISH. Bidders should note that the Members of the Syndicate/ SCSBs/Registered Brokers/RTA/CDPs will not be liable for errors in data entry due to incomplete or illegible Revision Forms; c. Ensure that Acknowledgment Slip for your Bid and any other applicable documents in support of the revision are attached with the Revision Form; and d. Bidders shall only be required to issue instruction to block the revised amount in excess of their original blocked amount based on the cap of the revised Price Band upon an upward revision of their Bid.
- Revision(s) in the Bid, the Bidders/Applicants will have to use the services of the same Designated Intermediary through which their Bidder/Applicant had placed the original Bid. Bidders/Applicants are advised to retain copies of the blank Revision Form and the Bid(s) must be made only in such Revision Form or copies thereof. Investors must ensure that their PAN is linked with Aadhaar and are in compliance with the notification by the Central Board of Direct Taxes dated February 13, 2020 read with press releases dated June 25, 2021 and September 17, 2021 read with press release dated September 17, 2021. CBDT circular no. 7 of 2022, dated March 30, 2022, read with press release dated March 28, 2023.

## OFFER STRUCTURE

Particulars	QIBs <sup>(1)</sup>	Non-Institutional Bidders	Retail Individual Bidders
Number of Equity Shares available for Allotment/ allocation <sup>(2)</sup>	Not more than [●] Equity Shares of face value ₹2 each	Not less than [●] Equity Shares of face value ₹2 each available for allocation	Not less than [●] Equity Shares of face value ₹2 each available for allocation
Percentage of Offer Size available for Allotment/ allocation	Not more than 50% of the Offer shall be Allotted to QIBs. However, up to 5% of the Net QIB Portion (excluding Anchor Investor Portion) will be available for allocation proportionately to Mutual Funds only. Mutual Funds participating in the Mutual Fund Portion will also be eligible for allocation in the remaining Net QIB Portion. The unsubscribed portion in the Mutual Fund Portion will be available for allocation to QIBs in the remaining Net QIB Portion.	Not less than 15% of the Offer or the Offer less allocation to QIB Bidders and RIBs will be available for allocation subject to the following: Further, one-third of the Non-Institutional Portion will be made available for allocation to Bidders with a Bid size of more than ₹0.20 million and up to ₹1.00 million and two-thirds of the Non-Institutional Portion will be available for allocation to Bidders with a Bid size of more than ₹1.00 million and under-subscription in either of these two subcategories of the Non-Institutional Portion may be allocated to Bidders in the other subcategory of the Non-Institutional Portion in accordance with the SEBI ICDR Regulations, subject to valid Bids being received at or above the Offer Price	Not less than 35% of the Offer or Offer less allocation to QIBs and Non- Institutional Bidders will be available for allocation
Basis of Allotment/ allocation if respective category is oversubscribed*	Proportionate as follows (excluding the Anchor Investor Portion): a) [●] Equity Shares of face value ₹2 each shall be available for allocation on a proportionate basis to Mutual Funds only; and b) [●] Equity Shares of face value ₹2 each shall be allotted on a proportionate basis to all QIBs, including Mutual Funds receiving allocation as per (a) above. Up to 60% of the QIB Portion Equity Shares may be allocated on a discretionary basis to Anchor Investors of which one-third shall be available for allocation to domestic Mutual Funds only, subject to valid Bid received from domestic Mutual Funds at or above the Anchor Investor Allocation Price	The Equity Shares available for allocation to Bidders in the Non-Institutional Portion shall be subject to the following: (a) One-third of the Non-Institutional Portion shall be available for allocation to Bidders with an application size more than ₹0.20 million upto ₹1.00 million; and (b) Two-thirds of the Non- Institutional Portion shall be available for allocation to Bidders with an application size of more than ₹1.00 million. Provided that the unsubscribed portion in either of these two sub-categories of Non- Institutional Portion may be allocated to the Bidders in the other sub-category of Non- Institutional Portion in accordance with SEBI ICDR Regulations. The allotment to each Non-Institutional Bidder shall not be less than the Minimum NIB Bid Size, subject to availability of Equity Shares in the Non-Institutional Portion and the remaining available Equity Shares, if any, shall be allotted on a proportionate basis, in accordance with SEBI ICDR Regulations.	The allotment to each Retail Individual Bidder shall not be less than the minimum Bid Lot, subject to availability of Equity Shares in the Retail Portion and the remaining available Equity Shares if any, shall be allotted on a proportionate basis. For details, see "Offer Procedure" beginning on page 418 of the RHP.
Mode of Bid	Only through the ASBA process (except for Anchor Investors)SEBI through its circular (SEBI/HO/CFD/DIL2/CIR/P/2022/45) dated April 5, 2022, has prescribed that all individual investors applying in initial public offerings opening on or after May 1, 2022, where the application amount is up to ₹ 0.50 million, shall use UPI. Individual investors bidding under the Non-Institutional Portion bidding for more than ₹0.20 million and up to ₹ 0.50 million shall be required to use the UPI Mechanism.		
Minimum Bid	Such number of Equity Shares in multiples of [●] Equity Shares of face value ₹2 each so that the Bid Amount exceeds ₹0.20 million	Such number of Equity Shares in multiples of [●] Equity Shares of face value ₹2 each so that the Bid Amount exceeds ₹0.20 million	[●] Equity Shares of face value ₹2 each
Maximum Bid	Such number of Equity Shares in multiples of [●] Equity Shares of face value ₹2 each so that the Bid does not exceed the size of the Offer, subject to applicable limits, applicable to each Bidder	Such number of Equity Shares in multiples of [●] Equity Shares of face value ₹2 each so that the Bid does not exceed the size of the Offer, (excluding the QIB Portion), subject to applicable limits, applicable to each Bidder	Such number of Equity Shares in multiples of [●] Equity Shares of face value ₹2 each so that the Bid Amount does not exceed ₹0.20 million
Bid Lot	[●] Equity Shares of face value ₹2 each and in multiples of [●] Equity Shares of face value ₹2 each thereafter		
Mode of allotment	Compulsorily in dematerialised form		
Allotment lot	[●] Equity Shares of face value ₹2 each and in multiples of one Equity Share thereafter		
Trading lot	One Equity Share of face value ₹2 each		
Who can apply <sup>(3)</sup>	Public financial institutions as specified in section 2(72) of the Companies Act 2013, scheduled commercial banks, Mutual Funds, FPIs other than individuals, corporate bodies and family offices, VCFs, AIFs, FVCIs, multilateral and bilateral development financial institutions, state industrial development corporation, insurance companies registered with IRDAI, provident funds (subject to applicable law) with minimum corpus of ₹250 million, pension funds with minimum corpus of ₹250 million registered with the Pension Fund Regulatory and Development Authority, National Investment Fund set up by the Government, the insurance funds set up and managed by army, navy or air force of the Union of India, insurance funds set up and managed by the Department of Posts, India and NBFC-SI	Resident Indian individuals, Eligible NRIs, HUFs (in the name of the karta), companies, corporate bodies, scientific institutions societies, trusts, family offices and FPIs who are individuals, corporate bodies and family offices	Resident Indian individuals, Eligible NRIs and HUFs (in the name of the karta)
Terms of payment	<b>In case of Anchor Investors:</b> Full Bid Amount shall be payable by the Anchor Investors at the time of submission of their Bids <sup>(4)</sup> <b>In case of all other Bidders:</b> Full Bid Amount shall be blocked in the bank account of the ASBA Bidder (other than Anchor Investors) or by the Sponsor Bank(s) through the UPI Mechanism (for Eligible Employees, RIBs or individual investors bidding under the Non – Institutional Portion for an amount of more than ₹0.20 million and up to ₹ 0.50 million, using the UPI Mechanism), that is specified in the ASBA Form at the time of submission of the ASBA Form		

\* Assuming full subscription in the Offer.

<sup>(1)</sup> Our Company in consultation with the BRLMs, may allocate up to 60% of the QIB Portion to Anchor Investors on a discretionary basis, in accordance with the SEBI ICDR Regulations. One-third of the Anchor Investor Portion shall be reserved for domestic Mutual Funds, subject to valid Bids being received from domestic Mutual Funds at or above the price at which allocation is being made to other Anchor Investors. For details, see "Offer Procedure" beginning on page 418 of the RHP.

<sup>(2)</sup> Subject to valid Bids being received at or above the Offer Price. This Offer is being made in accordance with Rule 19(2)(b) of the SCRR and under Regulation 6(1) of the SEBI ICDR Regulations. Under-subscription, if any, in the Non-Institutional Portion or the Retail Portion would be allowed to be met with spill-over from other categories or a combination of categories at the discretion of our Company in consultation with the BRLMs and the Designated Stock Exchange, on a proportionate basis. However, under-subscription, if any, in the QIB Portion will not be allowed to be met with spill-over from other categories or a combination of categories.

<sup>(3)</sup> If the Bid is submitted in joint names, the Bid cum Application Form should contain only the name of the First Bidder whose name should also appear as the first holder of the depository account held in joint names. The signature of only the First Bidder would be required in the Bid cum Application Form and such First Bidder would be deemed to have signed on behalf of the joint holders. Bidders will be required to confirm and will be deemed to have represented to our Company, the Selling Shareholders, the Underwriters, their respective directors, officers, agents, affiliates and representatives that they are eligible under applicable law, rules, regulations, guidelines and approvals to acquire the Equity Shares.

<sup>(4)</sup> Full Bid Amount shall be payable by the Anchor Investors at the time of submission of the Anchor Investor Application Form, provided that any difference between the price at which Equity Shares are allocated to the Anchor Investors and the Anchor Investor Offer Price, shall be payable by the Anchor Investor pay-in date as mentioned in the CAN.



